12211
Observational Cohort Prospective Study of Diagnostics of Coronavirus Disease 2019 Cardiovascular Complications Using Remote Electrocardiogram Monitoring and Pulse Wave
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT05608603/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Статус исследования в реестре не указан — уточняйте в центре.
- Возраст участников: 18–80 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 100 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановая дата окончания (11.2025) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 13 · невключение: 6
Критерии включения
- Written informed consent to participate in the study;
- Age 18 and over;
- Male and female;
- COVID-19 infection confirmed by laboratory tests (polymerase chain reaction testing, enzyme-linked immunosorbent assay (positive result at least 1 time) with a CT degree more that 25% of lung lesion.
- No more than 3 months after discharge from infectious department
- Non-inclusion criteria:
- Unable to sign informed consent;
- Mental illness (severe dementia, schizophrenia, severe depression, manic-depressive psychosis);
- Acute coronary syndrome, acute cerebrovascular accident, pulmonary embolism within the last 3 months;
- Oncology;
- Diseases and conditions that can change the ECG picture and complicate the analysis of the ECG (conduction disturbance, pacemaker);
- Inability to use a heart monitor (congenital developmental anomalies, traumatic amputation of the upper limbs, essential tremor, Parkinson's disease);
- Severe comorbidities with life expectancy less than 1 year.
Критерии невключения
- Refusal to further participation in the study;
- Acute infectious diseases, tuberculosis
- Oncology arising in the process of the study
- Acute coronary syndrome, acute cerebrovascular accident, pulmonary embolism arising in the process of the study
- Acute psychotic reactions arising in the process of the study;
- Inability to use a heart monitor arising in the process of the study
Источник: ClinicalTrials.gov, NCT05608603 · запись обновлена в реестре 20 марта 2024.
Дизайн и результаты
Что измеряют — первичные конечные точки (10)
- Changes in endothelin-1 in dynamics (compared with initial indicators) — In 9 months after the recovery from COVID-19
- Changes in the diastolic function of the right and left ventricles (compared with initial indicators) — In 9 months after the recovery from COVID-19
- Change in ejection fraction (compared with initial indicators) — In 9 months after the recovery from COVID-19
- Changes in the volumes of the heart cavities (compared with initial indicators) — In 9 months after the recovery from COVID-19
- Change in speed indicators on the heart valves (compared with initial indicators) — In 9 months after the recovery from COVID-19
- Change in mean and diastolic pressure of the pulmonary artery (compared with initial indicators) — In 9 months after the recovery from COVID-19
- Changes in the cardio-ankle vascular index and ankle-brachial index (compared with initial indicators) — In 9 months after the recovery from COVID-19
- Changes in the spectrum of volatile organic compounds in exhaled air in patients after COVID-19 infection over time (compared with initial indicators) — In 9 months after the recovery from COVID-19
- Change in oxygen pulse (VO2/HR) at the peak of the load — In 9 months after the recovery from COVID-19
- Changes in ventilation parameters (tidal volume (Vt), minute ventilation (VE), Vt/FVC index (ratio of tidal volume to forced vital capacity), respiratory reserve (BR)) over time — In 9 months after the recovery from COVID-19
Цель исследования
Aim of this prospective, observational, multi-centered, randomized study is to detect cardiovascular complications in patients after coronavirus infection.
The study will include 100 patients who underwent confirmed by laboratory tests COVID-19 infection (polymerase chain reaction (PCR) testing, enzyme-linked immunosorbent assay (positive result at least 1 time)) 1-3 months ago with the degree of lung lesion more than 25%, who were admitted to the University Clinical Hospital No. 4 of I.M. Sechenov First Moscow State Medical University.
The study consists of 4 periods:
1. Screening for up to 6 months.
2. Inclusion in the study, undergoing of identical laboratory and instrumental testing.
3. Re-examination of patients. After 6 months from the initial examination (9 months after discharge from the infectious diseases department), patients will be re-examined.
4 Determination of end points, statistical data processing.
Estimated result of the study is to confirm or refute the hypothesis:
1. As a result of the analysis of ECG and pulse wave data and comparison with echocardiography data, identify cardiovascular complications of COVID-19 infection.
2. To determine the diagnostic significance of pulse wave parameters for assessing cardiovascular complications in patients with a history of COVID-19 infection (sensitivity, specificity, positive and negative predictive value).
3. Identify correlations between pulse wave parameters and biochemical markers of endothelial dysfunction (endothelin-1).
4. As a result of the analysis of exhaled air by the proton mass spectrometry, to identify markers of cardiovascular complications in patients after COVID-19 infection.
5. As a result of a cardiorespiratory stress test, determine the respiratory and cardiovascular causes of dyspnea, exercise tolerance of patients after infection with COVID-19.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT05608603 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.